KFDA to approve GSK's new anesthetic drug, Ultiva
Ultiva (Remifentanil Hcl) was first approved as a new systemic anesthetic drug in 1996 and its additional indications for a sedative analgesia was approved in Europe in March 2002. It shows many advantages for the physician t...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
